SAN DIEGO--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, announced its official launch today.

圣地亚哥——（商业新闻短讯）——Candid Therapeutics，Inc.（“Candid”）是一家致力于开发潜在转化药物以治疗自身免疫性疾病的生物技术公司，今天宣布正式推出。

Recent groundbreaking clinical data has showcased the pivotal role of a specific subset of immune cells, B lymphocytes, in autoimmune diseases. B lymphocytes lead to autoimmune pathology by producing autoantibodies that attack the body's own tissues and also through antigen presentation and cytokine release.

最近开创性的临床数据显示了特定免疫细胞亚群B淋巴细胞在自身免疫性疾病中的关键作用。B淋巴细胞通过产生攻击身体自身组织的自身抗体以及通过抗原呈递和细胞因子释放而导致自身免疫病理。

Selective depletion of B lymphocytes has shown unprecedented clinical efficacy in highly refractory patients across multiple autoimmune diseases such as rheumatoid arthritis and myasthenia gravis. Candid is developing T-cell engager (“TCE”) antibodies that can deplete specific B lymphocyte cell populations and aims to be the first company to bring these novel therapies to market..

选择性消耗B淋巴细胞在多种自身免疫性疾病（如类风湿性关节炎和重症肌无力）的高度难治性患者中显示出前所未有的临床疗效。Candid正在开发可以消耗特定B淋巴细胞群的T细胞参与者（“TCE”）抗体，旨在成为第一家将这些新型疗法推向市场的公司。。

To accelerate development of and position Candid to become the leader in TCE antibodies for autoimmune diseases, Candid acquired Vignette Bio and TRC 2004 through a simultaneous three-way merger and multi-step financing. This acquisition integrates two cutting-edge bispecific TCEs:

为了加快自身免疫性疾病TCE抗体的开发并使Candid成为其领导者，Candid通过同时进行的三方合并和多步融资收购了Vignette Bio和TRC 2004。此次收购整合了两个尖端的双特异性TCE：

CND106, a BCMAxCD3 bispecific antibody from Vignette Bio, which was initially founded by Foresite Labs who exclusively licensed ex-China rights for the drug candidate from EpimAb Biotherapeutics.

CND106是来自Vignette Bio的BCMAxCD3双特异性抗体，最初由Foresite实验室成立，该实验室专门为EpimAb Biotherapeutics的候选药物授予了中国境外的权利。

CND261, a CD20xCD3 bispecific antibody from TRC 2004, which was established through a collaboration between Two River and Third Rock Ventures who exclusively licensed ex-China rights for the drug candidate from Genor Biopharma.

CND261是TRC 2004的一种CD20xCD3双特异性抗体，它是通过两家River和Third Rock Ventures的合作建立的，他们专门为Genor Biopharma的候选药物授予了中国境外的权利。

CND106 and CND261 have both completed Phase 1 dose escalation studies with combined data in over 130 oncology patients. Both drug candidates have shown potential to become best-in-class therapies for various autoimmune diseases.

CND106和CND261均已完成了1期剂量递增研究，并结合了130多名肿瘤患者的数据。两种候选药物都显示出成为各种自身免疫性疾病最佳治疗方法的潜力。

The founding Candid team includes an accomplished set of seasoned entrepreneurs who have repeatedly advanced nascent ideas into late-stage development products and commercialization.

成立的坦诚团队包括一批经验丰富的企业家，他们反复将新生想法推进后期开发产品和商业化。

Ken Song, MD as Chairman, President and CEO has successfully led several life science companies with over $5.5 billion in realized shareholder value. Most recently he led RayzeBio, a radiopharmaceutical company, from concept to Phase 3 in just over 3 years and negotiated a $4.1 billion sale of the company earlier this year to Bristol Myers Squibb..

医学博士Ken Song担任董事长、总裁兼首席执行官，成功领导了几家生命科学公司，实现股东价值超过55亿美元。最近，他带领放射性制药公司RayzeBio在短短3年多的时间里从概念到第三阶段，并在今年早些时候与百时美施贵宝谈判了将该公司以41亿美元的价格出售给百时美施贵宝。。

Timothy Lu, MD, PhD as Chief Medical and Scientific Officer was instrumental in the clinical development of novel oral IL-17 drugs for autoimmune diseases at DICE Therapeutics which was acquired last year by Eli Lilly, where he stayed on until joining the Candid team.

医学博士Timothy Lu作为首席医学和科学官，在DICE Therapeutics的新型口服IL-17药物治疗自身免疫性疾病的临床开发中发挥了重要作用，DICE Therapeutics去年被礼来公司收购，他一直留在那里，直到加入Candid团队。

Bernie Huyghe, PhD as Chief Technology Officer has over 30 years of experience in manufacturing of biologics and other complex therapeutic products and prior to Candid, was overseeing two Phase 3 antibody programs at Viridian Therapeutics.

伯尼·惠格（BernieHuyghe）博士是首席技术官，在生物制剂和其他复杂治疗产品的制造方面拥有30多年的经验，在Candid之前，他曾监督Viridian Therapeutics的两个3期抗体项目。

Arvind Kush as Chief Financial and Business Officer has had an illustrious career first as a managing director in healthcare banking at Bank of America before transitioning to RayzeBio as CFO where he navigated a highly successful oversubscribed IPO in September 2023.

Arvind Kush作为首席财务官和业务官，在美国银行（Bank of America）担任医疗保健银行业务董事总经理之前，他有着杰出的职业生涯，后来转任RayzeBio担任首席财务官，并于2023年9月成功完成了超额认购的首次公开募股（IPO）。

In conjunction with the merger, Candid has successfully raised over $370 million in capital from an extensive roster of investors, which includes a recently completed financing co-led by Venrock Healthcare Capital Partners, Fairmount, TCGX, and venBio Partners. Other notable healthcare investors supporting the company include Foresite Capital, Third Rock Ventures, Fidelity Management & Research Company, Samsara BioCapital, Qiming Venture Partners USA, OrbiMed, Boxer Capital, Redmile Group, Vida Ventures, Two River, Franklin Templeton, LifeSci Venture Partners, Mirae Asset Capital Life Science, Polaris Innovation Fund, Soleus Capital and other reputable institutional and mutual fund investors.

在合并的同时，Candid成功地从众多投资者手中筹集了3.7亿美元的资金，其中包括最近完成的由Venrock Healthcare capital Partners、Fairmount、TCGX和venBio Partners共同领导的融资。支持该公司的其他著名医疗保健投资者包括Foresite Capital、Third Rock Ventures、Fidelity Management&Research company、Samsara BioCapital、Qiming Venture Partners USA、OrbiMed、Boxer Capital、Redmile Group、Vida Ventures、Two River、Franklin Templeton、LifeSci Venture Partners、Mirae Asset Capital Life Science、Polaris Innovation Fund、Soleus Capital和其他著名的机构。

This substantial financial backing highlights strong investor confidence in Candid's purposeful approach and strategic vision, positioning the company for significant impact in bringing forth first-in-class therapies to patients with autoimmune diseases..

这一巨大的财务支持突显了投资者对Candid有目的的方法和战略愿景的强烈信心，使该公司在为自身免疫性疾病患者提供一流治疗方面产生了重大影响。。

“TCE antibodies have the most promise as scalable and patient friendly drugs to deplete B cells for treatment of a myriad of autoimmune conditions and represents a once in a generation development opportunity,” said Dr. Ken Song, Chairman, President, and CEO of Candid Therapeutics. “The drugs we are developing at Candid have the potential to go above and beyond the clinical and commercial success of Humira® and Rituxan® and I am thrilled to be leading the Candid team knowing we can possibly make history by changing the paradigm in how autoimmune diseases are treated.”.

Candid Therapeutics董事长、总裁兼首席执行官Ken Song博士表示：“TCE抗体作为可扩展且对患者友好的药物，最有希望消耗B细胞以治疗多种自身免疫性疾病，并代表了一个世代相传的发展机会。”。“我们在Candid开发的药物有可能超越Humira®和Rituxan®的临床和商业成功，我很高兴能够领导Candid团队，知道我们可以通过改变自身免疫性疾病的治疗模式来创造历史。”。

About Candid Therapeutics, Inc.

关于Candid Therapeutics，Inc。

Candid Therapeutics is an innovative biotechnology company dedicated to advancing the treatment of a range of immunological conditions. Established in 2024 and headquartered in San Diego, CA, Candid is driven by a team of repeatedly successful entrepreneurs with deep expertise and strong execution abilities.

Candid Therapeutics是一家创新的生物技术公司，致力于推进一系列免疫疾病的治疗。Candid成立于2024年，总部位于加利福尼亚州圣地亚哥，由一支拥有深厚专业知识和强大执行能力的屡获成功的企业家团队推动。

Supported by a distinguished syndicate of leading healthcare investors, Candid is committed to discovering and developing cutting-edge therapeutic programs that address significant unmet medical needs in immunology..

在领先医疗保健投资者的杰出财团的支持下，Candid致力于发现和开发前沿治疗计划，以解决免疫学中未满足的重大医疗需求。。

About Vignette Bio, Inc.

关于Vignette Bio，Inc。

Vignette Bio was formed in 2024. The company was incubated by Foresite Labs, an incubation platform led by an experienced team who believe that the tools of data science, when applied with scientific rigor, will greatly accelerate scientific discovery and the development of new products and services that benefit patients.

Vignette Bio成立于2024年。该公司由Foresite Labs孵化，Foresite Labs是一个孵化平台，由经验丰富的团队领导，他们相信数据科学工具在科学严谨的应用下，将大大加速科学发现以及有利于患者的新产品和服务的开发。

Vignette Bio was backed by Foresite Capital, Qiming Venture Partners, Samsara BioCapital, and Mirae Asset Capital Life Science..

Vignette Bio 得到了 Foresite Capital、启明创投、Samsara BioCapital 和未来资产资本生命科学部的支持。

About TRC 2004

关于TRC 2004

TRC 2004 was a company co-founded by Two River and Third Rock Ventures. Two River has founded some of the most successful cell therapy companies in the industry, including Kite Pharma (acquired by Gilead Sciences, Inc.). Third Rock Ventures is a leading healthcare venture firm that has raised $3.8 billion dollars since its inception, fueling investment in over 60 portfolio companies that have delivered numerous products to market across multiple therapeutic modalities and indications.

TRC 2004是由两家River和Third Rock Ventures共同成立的公司。Two River成立了一些业内最成功的细胞治疗公司，包括Kite Pharma（被Gilead Sciences，Inc.收购）。Third Rock Ventures是一家领先的医疗保健风险投资公司，自成立以来已筹集了38亿美元，推动了对60多家投资组合公司的投资，这些公司已通过多种治疗方式和适应症向市场提供了众多产品。